Broker Oriel said Lloyds Banking Group's offloading of TSB should enhance net interest margin for the bank and, with a rising dividend yield, has reiterated its 'buy' recommendation on the bank."This improvement should become apparent once TSB is deconsolidated, which will depend on how quickly Lloyds sells down its stake." Credit Suisse has kept its 'neutral' stance on medical device maker Smith & Nephew (S&N) but has said it sees upside to the share price if the rumoured takeover by US peer Stryker were to go ahead.The bank said that, assuming industry-typical merger synergies of around 9-11% of sales of the acquired entity - applied solely to S&N's Advanced Surgical Division - "we mechanically calculate a value of the merger synergies of about 160-195p/S&N share".IMI was trading higher after Swiss bank UBS lifted its rating on the stock from 'neutral' to 'buy', saying that growth rates of sales at the engineering group have the potential to double in the medium term."An organic sales compound annual growth rate (CAGR) of 3% over the last decade has not been impressive. However, we forecast a doubling of growth with an organic CAGR of 6.4% out to 2018," UBS said.Analysts at UBS have raised their price target on chipmaker Imagination Technologies from 200p to 250p as it looks forward to full-year results on June 24th. UBS said it believed delivery on a strong recovery in licensing in the second half, after two years of licensing weakness, is the "key next step" for the investment case.